Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: idasanutlin, navtemadlin, siremadlin +1 | 0.90 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 31 Parkinson's papers of 12,186 | 0.54 |
| pathways Reactome | 16 pathways; mostly vesicle traffic | 1.00 |
No case: the score is under the bar. Receipt 8572
Sealed predictions
- MDM2 in dopamine neurons, braak+0.78 (p 0.013) → -0.36 (p 0.347)receipt 8580
Swarm cases
receipt 8580: MDM2 in dopamine neurons, braak
- power
- full sample +0.21 (p 0.413, n 18), 95% CI -0.29 to +0.61. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.22 (p 0.374, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.27 (p 0.273, n 18). could be the mix.
- skeptic
- leave-one-out range +0.08 to +0.33, sign flips 0; without severely affected donors +0.21 (p 0.413, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for MDM2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts